ERBB2 and breast carcinoma: Our current study revealed difference in the cytotoxicity to HER2 positive breast cancer cells when trastuzumab was incubated with PBMCs from different healthy individuals, and several polymorphisms in immune function genes have been found related to this difference (data not shown).